These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16462632)

  • 21. Remission in schizophrenia: critical and systematic review.
    AlAqeel B; Margolese HC
    Harv Rev Psychiatry; 2012; 20(6):281-97. PubMed ID: 23216066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The use of Seroquel in schizophrenia].
    Chakhava VO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(9):63-4. PubMed ID: 11026140
    [No Abstract]   [Full Text] [Related]  

  • 23. Defining treatment refractoriness in schizophrenia.
    Brenner HD; Dencker SJ; Goldstein MJ; Hubbard JW; Keegan DL; Kruger G; Kulhanek F; Liberman RP; Malm U; Midha KK
    Schizophr Bull; 1990; 16(4):551-61. PubMed ID: 1981813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remission of positive and negative symptoms in refractory schizophrenia with a combination of haloperidol and quetiapine: Two case studies.
    Aziz MA; Pepler A; McNeely C; Gorman JM
    J Psychiatr Pract; 2006 Sep; 12(5):332-6. PubMed ID: 16998424
    [No Abstract]   [Full Text] [Related]  

  • 25. [The evaluation of long-term treatment with antipsychotics].
    Millet B
    Encephale; 2006 Dec; 32 Pt 3():S1072-5. PubMed ID: 17356502
    [No Abstract]   [Full Text] [Related]  

  • 26. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
    Dubois V; Peuskens J; Geerts P; Detraux J
    Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Kujawa et al. letter-to-the-editor.
    Sethuraman G; Taylor CC; Enerson M; Dunayevich E
    Schizophr Res; 2006 May; 84(1):172-3. PubMed ID: 16563702
    [No Abstract]   [Full Text] [Related]  

  • 29. Measuring remission in schizophrenia: response to Sethuraman et al., 2005.
    Kujawa M; Bossie CA; Lasser RA
    Schizophr Res; 2006 Mar; 83(1):109-10. PubMed ID: 16423505
    [No Abstract]   [Full Text] [Related]  

  • 30. Addition of reserpine to antipsychotic medication in refractory chronic schizophrenic outpatients.
    Bacher NM; Lewis HA
    Am J Psychiatry; 1978 Apr; 135(4):488-9. PubMed ID: 25024
    [No Abstract]   [Full Text] [Related]  

  • 31. Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Lepori T; Maccioni R; Milia P; Sarritzu E; Tusconi M; Carpiniello B;
    Psychiatry Res; 2013 Dec; 210(3):739-44. PubMed ID: 24007858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications for the pharmacotherapy of schizophrenia.
    Rep Group Adv Psychiatry (1984); 1992; (134):35-58. PubMed ID: 1348372
    [No Abstract]   [Full Text] [Related]  

  • 33. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment.
    Haro JM; Edgell ET; Jones PB; Alonso J; Gavart S; Gregor KJ; Wright P; Knapp M;
    Acta Psychiatr Scand; 2003 Mar; 107(3):222-32. PubMed ID: 12580830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine.
    Khouzam HR
    Depress Anxiety; 2000; 11(2):80-2. PubMed ID: 10812533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    Schizophr Res; 2011 Dec; 133(1-3):42-6. PubMed ID: 22000938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of therapeutic response in schizophrenia. A critical survey.
    Collins EJ; Hogan TP; Desai H
    Schizophr Res; 1991 Oct; 5(3):249-53. PubMed ID: 1684722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.
    Wobrock T; Köhler J; Klein P; Falkai P
    Acta Psychiatr Scand; 2009 Aug; 120(2):120-8. PubMed ID: 19392812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: the significance of symptoms, neuropsychological performance and cognitive biases.
    Andreou C; Roesch-Ely D; Veckenstedt R; Bohn F; Aghotor J; Köther U; Pfueller U; Moritz S
    Psychiatry Res; 2013 Dec; 210(3):729-34. PubMed ID: 23998362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.